Effects of Platelet Mimicking Nanoparticles in Patients With Cirrhosis (HEMCITAP)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06050993 |
Recruitment Status :
Not yet recruiting
First Posted : September 22, 2023
Last Update Posted : September 22, 2023
|
Tracking Information | |||
---|---|---|---|
First Submitted Date | July 7, 2023 | ||
First Posted Date | September 22, 2023 | ||
Last Update Posted Date | September 22, 2023 | ||
Estimated Study Start Date | October 15, 2023 | ||
Estimated Primary Completion Date | April 15, 2024 (Final data collection date for primary outcome measure) | ||
Current Primary Outcome Measures |
Area under the curve at 10 min of the T-TAS® 01 perfusion in PL chips [ Time Frame: One day ] | ||
Original Primary Outcome Measures | Same as current | ||
Change History | No Changes Posted | ||
Current Secondary Outcome Measures |
|
||
Original Secondary Outcome Measures | Same as current | ||
Current Other Pre-specified Outcome Measures | Not Provided | ||
Original Other Pre-specified Outcome Measures | Not Provided | ||
Descriptive Information | |||
Brief Title | Effects of Platelet Mimicking Nanoparticles in Patients With Cirrhosis | ||
Official Title | Exploration of Primary Haemostasis in Cirrhotic Patients With T-TAS System and Effects of Platelets Mimicking Nanoparticles | ||
Brief Summary | Haemostasis of cirrhotic patients is disturbed at different levels: primary haemostasis, coagulation and fibrinolysis, leading to a new haemostatic balance. Thrombocytopenia and thrombopathy are counterbalanced by elevation of Von Willebrand factor (VWF) and diminution of ADAMTS13 activity. Exploration of primary haemostasis is difficult in the laboratory, and non-interpretable in case of thrombocytopenia. Moreover, these tests are not performed under flow conditions. The T-TAS®01 system analyses the total haemostatic capacity in whole blood under shear stress, with chips coated with type 1 collagen. Platelets transfusion performs poorly in cirrhotic patients and is not recommended before invasive procedure. Platelets mimicking nanoparticles (PMNs) have been developed by Pr Sen Gupta (Case Western Reserve University, Cleveland, Ohio (OH), USA). PMNs have been proven to collaborate with platelets and enhance haemostasis in different shear conditions in vitro and in different models of haemorrhage in vivo. The assumption of this study is that the perfusions characteristics of cirrhotic patients in the T-TAS®01 system will be different from those of non-cirrhotic patients, and that platelets mimicking nanoparticles will improve these characteristics. | ||
Detailed Description | Hepatic cirrhosis is accompanied by an alteration of the haemostatic balance (primary haemostasis, coagulation, fibrinolysis). With regard to primary haemostasis, thrombocytopenia is usually moderate, due to splenic or hepatic sequestration associated with portal hypertension. Platelet synthesis is also reduced. There are also autoimmune thrombocytopenia due to the presence of anti-platelet autoantibodies. In addition, there is a thrombopathy with functional alterations in platelet adhesion and aggregation. In parallel with these abnormalities in platelet adhesion and aggregation, the quantitative increase in the level of Von Willebrand factor (VWF) preserves the capacity for platelet aggregation, even under conditions of circulating flow, despite the reduction in the intrinsic functional capacity of VWF. This increase can be explained by increased hepatic synthesis, a larger endothelial surface area in the presence of collateral circulation and repeated endothelial aggression by endotoximia during infections, as well as a decrease in clearance due to a decrease in the synthesis of ADAMTS13. Routine investigation of abnormalities in primary haemostasis is based almost exclusively on platelet counts, as well as plasma VWF and ADAMTS13 assays. Functional platelet tests (PFA®, impedance aggregometry, light transmission aggregation) are more difficult to perform, particularly in the case of thrombocytopenia, and are not performed under circulating flow conditions. The Total Thrombus Formation Analysis System (T-TAS®01) allows analysis of haemostatic capacity in whole blood and flow conditions. Whole blood is deposited in a reservoir and then perfused onto a type I collagen-coated chip (PL chip) at a shear rate of 1500 s-1, mimicking blood flow in small arteries. As the clot forms, the pressure in the perfusion chamber increases until total occlusion occurs. The parameters measured are :
Ex vivo, in the absence of endothelial injury, these SPs do not induce platelet aggregation in the absence of agonist but enhance aggregation in the presence of agonist. These SPs do not trigger thrombin formation on their own but in the presence of tissue factor SPs increase thrombin generation and fibrin formation. In perfusion chambers, these nanoparticles allow platelets to adhere to a collagen-coated surface and to aggregate with each other. In vivo, SPs collaborate with platelets to restore effective haemostasis in thrombocytopenic mice undergoing tail-clipping. Their haemostatic efficacy has also been demonstrated in various animal models of traumatic injury, including a mouse model of liver laceration, a porcine model of traumatic arterial haemorrhage, and a rodent model of liver resection. The assumption of this study is that the characteristics of infusions with the T-TAS®01 system will be altered in cirrhotic patients, reflecting impairment of primary haemostasis, compared to control patients and that platelet-mimicking nanoparticles (PMNs) will correct these alterations. |
||
Study Type | Observational | ||
Study Design | Observational Model: Case-Control Time Perspective: Prospective |
||
Target Follow-Up Duration | Not Provided | ||
Biospecimen | Retention: Samples Without DNA Description: 2 additional citrate tubes (total volume : 9 ml) and 1 Benzylsulfonyl-D-Arg-Pro-4-amidinobenzylamide (BAPA) tube (total volume : 3 ml) will be withdrawn at the same time and in addition of those already withdrawn for the patient's standard of care. Plasma aliquots will be done from citrate tubes and frozen. Whole blood tube will be used on the same day of sampling. |
||
Sampling Method | Non-Probability Sample | ||
Study Population | Patients coming to the Paul Brousse hospital for a scheduled preoperative procedure. | ||
Condition | Liver Cirrhosis | ||
Intervention | Other: Additional blood sampling at the same time and in addition of samplings already done for the patient's standard of care.
During the preoperative procedure scheduled at the Paul Brousse hospital, 3 additional blood tubes (total volume 12 ml) will be withdrawn in addition of samplings already done for the patient's standard of care.
|
||
Study Groups/Cohorts |
|
||
Publications * | Not Provided | ||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||
Recruitment Information | |||
Recruitment Status | Not yet recruiting | ||
Estimated Enrollment |
60 | ||
Original Estimated Enrollment | Same as current | ||
Estimated Study Completion Date | April 15, 2024 | ||
Estimated Primary Completion Date | April 15, 2024 (Final data collection date for primary outcome measure) | ||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
|
||
Sex/Gender |
|
||
Ages | 18 Years and older (Adult, Older Adult) | ||
Accepts Healthy Volunteers | Yes | ||
Contacts | |||
Listed Location Countries | France | ||
Removed Location Countries | |||
Administrative Information | |||
NCT Number | NCT06050993 | ||
Other Study ID Numbers | APHP230249 2023 -A00064-41 ( Other Identifier: IDRCB ) |
||
Has Data Monitoring Committee | No | ||
U.S. FDA-regulated Product | Not Provided | ||
IPD Sharing Statement |
|
||
Current Responsible Party | Assistance Publique - Hôpitaux de Paris | ||
Original Responsible Party | Same as current | ||
Current Study Sponsor | Assistance Publique - Hôpitaux de Paris | ||
Original Study Sponsor | Same as current | ||
Collaborators |
|
||
Investigators | Not Provided | ||
PRS Account | Assistance Publique - Hôpitaux de Paris | ||
Verification Date | July 2023 |